335 related articles for article (PubMed ID: 33537844)
1. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.
McCloskey EV; Johansson H; Harvey NC; Lorentzon M; Shi Y; Kanis JA
Osteoporos Int; 2021 Aug; 32(8):1601-1608. PubMed ID: 33537844
[TBL] [Abstract][Full Text] [Related]
2. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
4. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
[TBL] [Abstract][Full Text] [Related]
5. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
Lane J; Langdahl B; Stone M; Kurth A; Oates M; Timoshanko J; Wang Z; Libanati C; Cosman F
Osteoporos Int; 2024 Jul; 35(7):1195-1204. PubMed ID: 38573517
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
[TBL] [Abstract][Full Text] [Related]
7. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
McClung MR; Betah D; Deignan C; Shi Y; Timoshanko J; Cosman F
Endocr Pract; 2023 Sep; 29(9):716-722. PubMed ID: 37406858
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of teriparatide compared with risedronate on FRAX
Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
10. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.
Langdahl B; Hofbauer LC; Ferrari S; Wang Z; Fahrleitner-Pammer A; Gielen E; Lakatos P; Czerwinski E; Gimeno EJ; Timoshanko J; Oates M; Libanati C
Osteoporos Int; 2022 Dec; 33(12):2527-2536. PubMed ID: 36173415
[TBL] [Abstract][Full Text] [Related]
11. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.
McCloskey EV; Johansson H; Oden A; Harvey NC; Jiang H; Modin S; Fitzpatrick L; Kanis JA
J Bone Miner Res; 2017 Aug; 32(8):1625-1631. PubMed ID: 28474780
[TBL] [Abstract][Full Text] [Related]
13. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.
Cosman F; Crittenden DB; Ferrari S; Lewiecki EM; Jaller-Raad J; Zerbini C; Milmont CE; Meisner PD; Libanati C; Grauer A
J Bone Miner Res; 2018 Aug; 33(8):1407-1416. PubMed ID: 29750828
[TBL] [Abstract][Full Text] [Related]
14. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative hormone therapy trials.
Lorentzon M; Johansson H; Harvey NC; Liu E; Vandenput L; Crandall CJ; Cauley JA; LeBoff MS; McCloskey EV; Kanis JA
Osteoporos Int; 2022 Nov; 33(11):2297-2305. PubMed ID: 35833956
[TBL] [Abstract][Full Text] [Related]
16. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
[TBL] [Abstract][Full Text] [Related]
17. Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study.
Harvey NC; Odén A; Orwoll E; Lapidus J; Kwok T; Karlsson MK; Rosengren BE; Ribom E; Cooper C; Cawthon PM; Kanis JA; Ohlsson C; Mellström D; Johansson H; McCloskey E
J Bone Miner Res; 2018 Dec; 33(12):2150-2157. PubMed ID: 30011086
[TBL] [Abstract][Full Text] [Related]
18. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
19. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.
Geusens P; Feldman R; Oates M; Thomas T; Makras P; Jakob F; Langdahl B; Wang Z; Rojeski M; Libanati C
Bone; 2022 Jan; 154():116209. PubMed ID: 34547521
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada.
Leslie WD; Lix LM; Binkley N
Arch Osteoporos; 2020 Jun; 15(1):93. PubMed ID: 32577922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
